Enterprise Value
-29.2M
Cash
48.38M
Avg Qtr Burn
N/A
Short % of Float
2.58%
Insider Ownership
31.89%
Institutional Own.
31.46%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EQ001 (Itolizumab)(monoclonal antibody that targets CD6-ALCAM) Details Acute graft-versus host disease | Phase 3 Interim Update | |
EQ101 Details Celiac disease, Alopecia areata | Phase 2 Data readout | |
EQ001 (Itolizumab) Details Ulcerative colitis | Phase 2 Update | |
EQ001 (Itolizumab)(monoclonal antibody that targets CD6-ALCAM) Details Lupus nephritis, Systemic lupus erythematosus | Phase 1b Data readout | |
Phase 1b Update | ||
EQ102 Details Celiac disease | Phase 1 Data readout |